Glucose Metabolism Disorders  >>  Linjeta (prandial insulin)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Linjeta (prandial insulin) / Ipsen
NCT00542724 / 2006-006599-39: An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

Completed
3
462
US, Europe, RoW
VIAject™, Regular Human Insulin
Biodel
Type 1 Diabetes Mellitus
07/08
 
NCT00542633 / 2006-006600-11: An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus

Completed
3
472
US, Europe, RoW
VIAject™, Regular Human Insulin
Biodel
Type 2 Diabetes Mellitus
08/08
 
NCT00875108: An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes Mellitus

Checkmark Data
Jun 2011 - Jun 2011: Data
Completed
3
116
US, Europe, RoW
VIAject™
Biodel
Diabetes Mellitus
01/10
01/10
NCT00875459: An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 1 Diabetes Mellitus

Checkmark Data
Jun 2011 - Jun 2011: Data
Completed
3
233
US, Europe, RoW
VIAject™
Biodel
Diabetes Mellitus
02/10
02/10

Download Options